Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of phase II KJ103 desensitization in highly sensitized kidney transplant recipients
CTR20253750Phase 2Active
- Sponsor
- Shanghai Baoji Pharmaceutical
- Start
- Nov 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ricefidase in HLA sensitization, sponsored by Shanghai Baoji Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
ricefidase
03
Conditions
HLA sensitization
Beyond the preview
Go deeper on CTR20253750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253750.